Personality, coronary-prone behaviour and adrenergic factors in essential hypertension: possible implications for cardiac prevention. 1982

C Perini, and F Müller, and F R Bühler

An association between high blood pressure and the coronary-prone (or type A) behaviour pattern, established as risk factors for myocardial infarction and sudden death, has been postulated on the basis of similar psychophysiological mechanisms involving the sympathetic nervous system. Psychodynamic personality profiles and type A behaviour assessment have therefore been related to biochemical markers of sympathetic overactivity, but type A behaviour scores were generally found to be low in hypertensive subjects - and lowest in those with high plasma noradrenaline. However, projective assessment of reactions to frustration during everyday stress indicates that hypertensive patients with high plasma renin activity as well as high noradrenaline have less externalized but more internalized aggression, and are submissive yet have a stronger need to resolve conflicts immediately. These incompatible tendencies result in chronic frustration. A similar high degree of suppressed anger is shared by patients at risk for coronary heart disease, and high renin patients have a higher incidence of critical cardiac events. This suggests the possibility of a 'hypertensive coronary-prone personality'. Because of their excellent antihypertensive response to chronic beta-blocker therapy, it is conceivable that high renin patients benefit most from the cardioprotective potential of beta-blocker-based antihypertensive therapy.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010551 Personality Behavior-response patterns that characterize the individual. Personalities
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D001519 Behavior The observable response of a man or animal to a situation. Acceptance Process,Acceptance Processes,Behaviors,Process, Acceptance,Processes, Acceptance

Related Publications

C Perini, and F Müller, and F R Bühler
January 1982, Contributions to nephrology,
C Perini, and F Müller, and F R Bühler
September 1975, Journal of the Indian Medical Association,
C Perini, and F Müller, and F R Bühler
June 1994, Journal of the Royal Society of Medicine,
C Perini, and F Müller, and F R Bühler
July 1959, A.M.A. archives of internal medicine,
C Perini, and F Müller, and F R Bühler
January 1950, Psychosomatic medicine,
C Perini, and F Müller, and F R Bühler
May 1985, British journal of hospital medicine,
C Perini, and F Müller, and F R Bühler
October 2003, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology,
C Perini, and F Müller, and F R Bühler
May 1987, Casopis lekaru ceskych,
C Perini, and F Müller, and F R Bühler
January 1991, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!